Latest Breaking News On - City of hope cancer center - Page 8 : vimarsana.com

Myeloma: Isatuximab 4-Drug Regimen Boosts MRD Negativity

'This [research] builds on our experience that four-drug combinations with a monoclonal antibody, proteasome inhibitor, immunomodulatory drug, and steroids are superior to three-drug combinations.'

FDA OKs Iptacopan to Treat Paroxysmal Nocturnal Hemoglobinuria

This marks the first oral monotherapy approved for the rare blood disorder.

Imugene advances Phase 1 MAST trial for cancer-killing VAXINIA virus

Imugene Ltd (ASX:IMU, OTC:IUGNF) has made progress in its Phase 1 metastatic advanced solid tumours or MAST trial, which has been designed to evaluate the.

Imugene's B Cell immunotherapy and oncolytic virotherapy platforms shine at ESMO Congress

The B cell immunotherapy HER-Vaxx and CF33 oncolytic virotherapy CHECKVacc of Imugene Ltd (ASX:IMU, OTC:IUGNF) (Imugene Ltd (ASX:IMU, OTC:IUGNF), Imugene.

ESMO 2023: STELLAR-304: A Randomized Phase 3 Study of Zanzalintinib (XL092) and Nivolumab in Non-Clear Cell Renal Cell Carcinoma